James McCloskey - Concepedia

Author

James McCloskey

The University of Texas MD Anderson Cancer Center

Also Known As

J McCloskey, J. K. McCloskey, J. Mccloskey, J.K. McCloskey, James K McCloskey, James K Mccloskey, James K. McCloskey, James McCloskey, James Mccloskey, Zijing Zhang

156

Publications

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Hackensack University Medical Center University of Chicago Johns Hopkins University Hackensack Meridian Health

About

James McCloskey is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacotherapy, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	339
2	Health Sciences	4	4	220
3	Engineering	1	1	17
4	Cellular Therapies	1	1	127
5	Hepatology	1	1	14

James McCloskey

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Blood	2020	228
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma, Blood	2020	205
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Blood	2021	185
Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia Naval Daver, Alexander E. Perl, Joseph Maly, Journal of Clinical Oncology	2022	179
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure Brian Ball, Christopher Famulare, Eytan M. Stein, Blood Advances Cell TherapyOncologyMarrow TransplantationTransplantationKey Points	2020	127
Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS Michael R. Savona, Daniel A. Pollyea, Wendy Stock, Clinical Cancer Research	2018	105
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, JAMA	2024	90
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, The Lancet Haematology Hematological MalignancyOncologyHematologyPharmacologyChronic Myelomonocytic Leukaemia	2023	73
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Blood	2018	61
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine Guillermo Garcia‐Manero, James McCloskey, Elizabeth A. Griffiths, Blood	2019	60

Page 1